ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi? [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
This selloff comes as investors grow wary of Johnson & Johnson 's JNJ newly approved immunology therapy, Icotyde, which could emerge as a competitive threat to Skyrizi, a key growth driver for AbbVie. J&J announced yesterday that the FDA approved Icotyde, an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in patients aged 12 years and above who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. J&J noted that this approval marks a significant milestone, making Icotyde the first targeted oral peptide designed to precisely block the IL-23 receptor. Skyrizi has been a key pillar of AbbVie's growth strategy following Humira's loss of exclusivity, generating multi-billion-dollar annual sales and delivering strong double-digit growth since launch. The drug is currently the company's top-selling medication, with sales rising 50% year over year to $17.6 billion in 2025. Management expects Skyrizi to generate a
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Origin Materials and HP Embalagens enter PET cap distribution deal [Yahoo! Finance]Yahoo! Finance
- Barclays Sees Continued Strength in Johnson & Johnson (JNJ) Pharma Business [Yahoo! Finance]Yahoo! Finance
- Contact Lenses and Solutions Market to Reach USD 38.09 Billion by 2032 Amid Rising Vision Care Demand and Technological Advancements, Reports Vyansa Intelligence [Yahoo! Finance]Yahoo! Finance
- GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer [Yahoo! Finance]Yahoo! Finance
- $500 a Month in Passive Income Is Closer Than You Think With These 4 Dividend ETFs [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website